文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

终末期肾病患者的尿毒症性心包炎:2017年患病率、症状与结局

Uremic pericarditis in patients with End Stage Renal Disease: Prevalence, symptoms and outcome in 2017.
PubMed 文献 · Am J Emerg Med · 2017-11-21
一句话结论终末期肾病患者中尿毒症性心包炎罕见但可致命,因有心脏压塞风险,预后取决于早期诊断和充分的终末期肾病治疗。

这是一项回顾性研究(2015年5月至2017年9月),纳入16例终末期肾病合并尿毒症性心包炎患者,尿毒症性心包炎定义为终末期肾病患者在开始肾脏替代治疗前或开始后8周内发生的心包炎。患者中位年龄54岁,56.2%为男性;心包积液少量、中量和大量者分别占31.2%、37.6%和31.2%。1例因濒临心脏压塞的临床表现行心包穿刺,3例因心脏压塞行心包引流。所有患者均开始血液透析并持续2至3周直至心包积液完全消退,平均透析次数11±3.5次。1例患者死于诊断尿毒症性心包炎3周后发生的感染性休克。作者认为尿毒症性心包炎是终末期肾病罕见但致命的并发症,预后取决于早期诊断和充分的终末期肾病治疗。

要点

  • 终末期肾病患者出现尿毒症性心包炎时,心包积液少量、中量、大量分别占31.2%、37.6%、31.2%。
  • 16例患者中4例出现心脏压塞相关事件:1例因濒临心脏压塞行心包穿刺,3例因心脏压塞行心包引流。
  • 所有患者均开始血液透析并持续2至3周直至心包积液完全消退,平均透析次数11±3.5次。
  • 1例患者死于诊断尿毒症性心包炎3周后发生的感染性休克。
  • 作者认为尿毒症性心包炎是终末期肾病罕见但致命的并发症,预后取决于早期诊断和充分的终末期肾病治疗。

适用人群与场景

  • 终末期肾病患者,尿毒症性心包炎定义为在开始肾脏替代治疗前或开始后8周内发生的心包炎。

诊断标准与关键阈值

  • 尿毒症性心包炎定义:终末期肾病患者在开始肾脏替代治疗前或开始后8周内发生的心包炎。

处置流程与药物剂量

  • 所有患者均开始血液透析,并持续2至3周直至心包积液完全消退;平均透析次数11±3.5次。
  • 1例因濒临心脏压塞的临床表现行心包穿刺。
  • 3例因心脏压塞行心包引流。

红旗征与不能漏的情况

  • 濒临心脏压塞的临床表现:1例行心包穿刺。
  • 心脏压塞:3例行心包引流。

研究设计与关键结果

  • 回顾性研究(2015年5月至2017年9月),16例终末期肾病合并尿毒症性心包炎患者,中位年龄54[24,71]岁,56.2%为男性。
  • 心包积液少量、中量、大量分别占31.2%、37.6%、31.2%。
  • 1例因濒临心脏压塞行心包穿刺,3例因心脏压塞行心包引流。
  • 所有患者均开始血液透析并持续2至3周直至心包积液完全消退,平均透析次数11±3.5次。
  • 1例患者死于诊断尿毒症性心包炎3周后发生的感染性休克。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为尿毒症性心包炎是终末期肾病罕见但致命的并发症,因有心脏压塞风险,预后取决于早期诊断和充分的终末期肾病治疗。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: The prevalence of uremic pericarditis (UP) used to range from 3% to 41%. More recently, it has decreased to about 5%-20% and to <5% in the last decades, as hemodialysis techniques have become widely used and dialysis quality improved. The objective of this work is to determine the initial clinical picture and the prognosis of patients presenting End Stage Renal Disease (ESRD) with UP.

MATERIALS: This is a retrospective study (May 2015-September 2017). Inclusion criteria targeted patients who had uremic pericarditis defined as pericarditis occurring in a patient with ESRD before initiation of renal replacement therapy, or within eight weeks of its initiation.

RESULTS: 16 patients met the inclusion criteria. The median age of patients was 54 [24, 71] years and 56.2% were male. Pericardial effusion was small, moderate and large in 31.2%, 37.6% and 31.2% of cases respectively. One pericardiocentesis was performed in view of a clinical picture of impending cardiac tamponade and three pericardial drainages were performed given presentation of tamponade. Hemodialysis was initiated for all the patients and continued for 2 to 3weeks until complete regression of the pericardial effusion. The mean number of dialysis sessions was 11±3.5. One patient died of septic shock that developed three weeks after diagnosis of uremic pericarditis.

CONCLUSION: UP is considered a rare but fatal complication of ESRD because of the risk of tamponade and its prognosis remains dependent on early diagnosis and adequate treatment of ESRD.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Bentata Y, Hamdi F, Chemlal A, et al. Uremic pericarditis in patients with End Stage Renal Disease: Prevalence, symptoms and outcome in 2017. Am J Emerg Med. 2017. PMID: 29248269. doi:10.1016/j.ajem.2017.11.048

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。